The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Conatus Pharmaceuticals Significant Joint-Venture Review and Analysis of Third Quarter 2016 Results
Jan. 03, 2017 09:30AM PST
Technology Investing NewsConatus Pharmaceuticals (NASDAQ:CNAT) a biotechnology company focused on treating liver disease, announced earnings for the third quarter of 2016 on November 8, 2016. They are looked at by Traders News Source, an equity research firm specializing in small and micro-cap securities. As quoted in the press release: Based on current technology (and no regulatory approval …
Conatus Pharmaceuticals (NASDAQ:CNAT) a biotechnology company focused on treating liver disease, announced earnings for the third quarter of 2016 on November 8, 2016. They are looked at by Traders News Source, an equity research firm specializing in small and micro-cap securities.
As quoted in the press release:
Based on current technology (and no regulatory approval for drugs to treat cirrhosis), patients’ eventual solution is to seek a liver transplant. Unfortunately, demand exceeds supply by an overwhelming margin. Conatus stock is up over +80% in 2016. EPS loss of ($0.31) reflects continued investment in trails of CNAT’s liver treatment products. Given the recent announcement of the firm’s joint-venture with pharmaceutical company Novartis, focus will turn from funding to progress on trials of the company’s liver disease treatment.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.